Corporate - MM&M - Medical Marketing and Media


AbbVie | 2017

Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker’s most important product.

Amgen | 2017

Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.

Merck | 2017

The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.

Johnson & Johnson | 2017

After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.

Pfizer | 2017

Is Pfizer finally in a position to close the Lipitor chapter, the one titled “how to bounce back from monumental loss”? All signs indicate yes.

AstraZeneca | 2017

AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.

Eli Lilly | 2017

Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer’s disease drug solanezumab.